Pharma DECODED
Previous edition: 15 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Register Now
Now Software Inc has extended it time and contact management software, Now Up-to-date, to run under Windows. The Portland, Oregon-based company said the move would expand its corporate customer base. Now Software sells mainly to large corporates that use a mixed environment of Macintosh and Windows personal computers and therefore need software than will run under both operating systems. Now Up-to-Date includes QuickAccess Manager, a permanent on-screen toolbar that gives users access to schedules, name and numbers, and additional diary dates that when entered in the QuickPad automatically appear under the appropriate date. The company said that its main rival was Microsoft Corp's Schedule Plus, which is given away with Microsoft Office. Now said that it had the edge over Schedule Plus because Now Up-to-date ran under more operating systems. It claims to be compatible with Macintosh, Windows 3.1 and Windows95. Now said it is currently working on expanding its software so it can be accessed by remote users with Personal Digital Assistants and pagers. It is also looking at making the software available on corporate Web servers so that companies can offer this information as part of their Web sites. The single-user version costs #100 and will be available this week. The workgroup edition for five users will costs #475, a 10-user version will costs #875 and a 50-user version will cost #3,900. Workgroup editions will be shipping next month.
Latest news
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
CircRNA is still in very early days of development, but it is expected to trialled in vaccines, therapeutics and biomarkers trials in the next few years.
AbbVie makes psychedelic play with $2bn Gilgamesh collaboration
The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.
Bayer reports drop in Q1 sales amidst patent litigation challenges
Bayer announced a fall in Q1 sales and predicted future challenges in the Xarelto market in its Q1 update.
OCT Europe: Unless everyone is benefiting, what is the point?
A big topic at Arena International’s Outsourcing in Clinical Trials Europe 2024 is how everyone should benefit from clinical research.
NeuroSense taps PhaseV's ML tech for Phase III ALS trial analysis
PhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase III trial design, enrolment, and cost-effectiveness.
AriBio receives approval from China's NMPA to begin Alzheimer's treatment trial
The study aims to assess the efficacy and safety of AR1001 in treating patients with early Alzheimer's disease.
Medidata expands clinical trial software partnership with Worldwide Clinical Trials
The collaboration aims to help Worldwide's customers reduce trial timelines and improve site selection.
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
The company plans to begin the subsequent Phase II expansion study in the second half of this year.
15th Annual Outsourcing in Clinical Trials East Coast 2024
The upcoming Outsourcing in Clinical Trials Europe 2024 conference will explore advancements in the clinical trial industry.
In our previous edition
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Pharma Decoded
Takeda tackles $900m restructuring plan after generics hurt annual profits
10 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer